Pfizer Inc.'s Back-Pain Medication Meets Primary Phase 3 Goals
Published: Jan 23, 2014
Pfizer Inc. (PFE: Quote) reported top-line results of Phase 3 trial of investigational agent ALO-02 in patients with moderate-to-severe chronic low back pain. During this study, ALO-02 met the primary efficacy endpoint, showing a statistically significant difference from placebo.
Help employers find you! Check out all the jobs and post your resume.